HER2 Breast Cancer

Latest News

Woman with a pink ribbon for breast cancer awareness -- Image credit: Phongsakorn | stock.adobe.com
ASCO 2025: Ribociclib With NSAI in HR+/HER– Breast Cancer Improves iDFS, Yields Substantial Work Productivity Gains

June 13th 2025

Ribociclib in combination with a nonsteroidal aromatase inhibitor (NSAI) improved invasive disease-free survival (iDFS) while allowing for better quality of life in hormone receptor-positive (HR+)/human epidermal growth receptor 2-negative (HER2−) early breast cancer.

HER2+ breast cancer -- Image credit: Chutima | stock.adobe.com
ASCO 2025: THP Without Carboplatin Shows Noninferior pCR Rates, Improved Tolerability in HER2+ Early Breast Cancer

June 9th 2025

HER2 breast cancer -- Image credit: David A Litman | stock.adobe.com
ASCO 2025: Vepdegestrant Shows Superiority to Fulvestrant in ER+/HER2- Advanced Breast Cancer

June 9th 2025

Scan of breast cancer -- Image credit: Science RF | stock.adobe.com
ASCO 2025: Camizestrant With CDK4/6 Inhibitor Improves PFS in Patients With HR+/HER2- Advanced Breast Cancer

June 5th 2025

X-ray of tumor on a patient's breast -- Image credit: peterschreiber.media | stock.adobe.com
ASCO 2025: Vepdegestrant's Efficacy and Safety in ER+/HER2- Advanced Breast Cancer

June 2nd 2025

<1
...
34567